Comparative pharmacokinetics of cyclophosphamide administration alone and combination with vitamin B6 in rats

Abstract

A fast and sensitive high performance liquid chromatography coupled with mass spectrometry (LC-MS) method was developed and validated for the determination of cyclophosphamide in rat plasma with and without the combination of vitamin B6. After addition of digoxin used as the internal standard (IS), plasma samples were extracted by protein precipitation with acetonitrile (1:1, v/v), and the analytes were separated by a Kromasil C18 column (150 × 4.6 mm, 5 µm) with a mobile phase of acetonitrile-0.1% formic acid water (40:60, v/v). The detection of the analyte was monitored in positive electrospray ionization by selected ion monitoringmode. The linear range was 0.01-40 µg/mL for cyclophosphamide. The intra- and inter-day precision and accuracy were all <15%. The extraction recoveries and matrix effects of the analyte and IS were all within acceptable range. The selectivity of the method was satisfactory with no endogenous interference. The results for stabilities of cyclophosphamide and IS under various conditions were all within the acceptance criteria. The validated method was successfully applied to evaluate the drug-drug interaction of cyclophosphamide and vitamin B6 in rat plasma. The results showed no differences of pharmacokinetic behaviors between cyclophosphamide administration with and without vitamin B6.

Ginsenoside Rh2 reverses cyclophosphamide-induced immune deficiency by regulating fatty acid metabolism

“…showed pairing targeted therapeutics with subtherapeutic doses of broad acting “network brake” drugs extended therapeutic utility while reducing whole body toxicity. Since its first discovery, CY has been used as an anticancer drug for more than 40 years in clinical practice, and remains to be a main chemotherapy drug for multiple cancers . Despite its significant therapeutic effects, the serious toxicity and side effects of CY have remained a major hindrance on the prognosis and quality of life of patients.…”

LLLT enhance cyclophosphamide induced TRPM2 channel activation in human colon cancer cells

“…Cyclophosphamide (CP) is widely used in the treatment of numerous malignant diseases and in the treatment of colon cancer. CP stimulates apoptosis as the result of interaction with cellular macromolecules such as: proteins, membrane lipids, RNA and DNA (2). In animal model studies performed during the last decade, CP, which has been suggested as a salvage therapy in low doses to prevent tumour angiogenesis in end-stage cancer patients, has also been shown to have an immunomodulatory effect (3).…”